Totus Medicines reports Phase 1a data for TOS-358
Totus Medicines unveiled promising Phase 1a clinical data for TOS-358 at ESMO TAT 2026, showcasing a 50% clinical benefit rate and a 75% disease control rate among participants. Presented by Dr. Antonio Giordano from Dana Farber Cancer Center, the findings reveal that 40% of patients experienced at least a 20% tumor shrinkage, while 45% remained on treatment for 24 weeks or longer. Notably, TOS-358 showed a 67% disease control rate in patients resistant to PI3K AKT mTOR therapies.
This data is significant for the longevity and healthspan fields as it highlights TOS-358’s potential in treating difficult-to-manage cancers, particularly in patients who have exhausted other therapeutic options. The differentiated safety profile, with minimal severe side effects, further underscores its promise as a viable treatment alternative.
As Totus initiates a Phase 1b trial to explore combinations with fulvestrant and CDK4/6 inhibitors, the evolving landscape of targeted cancer therapies may soon benefit from these insights. For a deeper dive into the findings, I encourage you to read the full article.